Gynecologic Management of BRCA-Positive Women

Introduction

BRCA1 and BRCA2 are well-established genes associated with a markedly increased risk of breast and ovarian cancers. Women who are BRCA-Positive face significantly higher lifetime risks compared to the general population, making early identification and proactive management crucial.

A strong family history of these malignancies often serves as the first clue for clinicians, signalling the potential presence of BRCA-Positive status. Recognising patterns of inherited cancer within families allows healthcare providers to stratify risk accurately and implement timely interventions.

The primary aim of this article is to provide a practical, evidence-based guide for obstetricians and gynaecologists, enabling them to offer comprehensive care to women who are BRCA-Positive. This encompasses genetic counselling, personalised surveillance, consideration of risk-reducing surgery, and multidisciplinary support tailored to each patient’s needs.

Genetic Testing and Counselling

All women with a family history suggestive of hereditary breast or ovarian cancer should be promptly referred for genetic counselling. Identifying individuals who are BRCA-Positive at an early stage allows clinicians to accurately stratify risk and implement personalised management strategies.

Early detection of BRCA-Positive status not only informs decisions regarding surveillance and risk-reducing interventions but also provides valuable guidance for family members who may be at risk. Evidence-based guidelines from the National Comprehensive Cancer Network (NCCN), the US Preventive Services Task Force, and the American College of Obstetricians and Gynaecologists (ACOG) strongly recommend systematic genetic assessment for at-risk populations.

🧬 Individualised Surveillance for BRCA-Positive Women

For women who are BRCA-Positive, personalised surveillance is essential for early detection and improved outcomes. Monitoring strategies are tailored to individual risk factors, age, gene variant, and family history.

Enhanced Imaging

Annual breast MRI and mammography are recommended, typically starting between ages 25 and 30, depending on the patient’s risk profile. These imaging modalities help detect abnormalities at the earliest possible stage.

Clinical Breast Examinations

Regular clinical breast exams remain a key component of surveillance, allowing healthcare providers to identify any changes or abnormalities promptly. This complements imaging and ensures a comprehensive monitoring approach.

Personalised Surveillance Protocols

Surveillance plans are customised according to age, specific gene variant, and family history. Personalised protocols maximise early detection while minimising unnecessary interventions, ensuring optimal outcomes for BRCA-Positive women.

Early detection matters. Individualised surveillance empowers BRCA-Positive women and clinicians to detect cancer early, take preventive action, and improve long-term health outcomes.

Risk-Reducing Surgery

For women who are BRCA-Positive, risk-reducing surgical interventions play a pivotal role in lowering the incidence of breast and ovarian cancers.

Risk-Reducing Salpingo-Oophorectomy (RRSO)

RRSO is recommended for BRCA1 carriers between the ages of 35 and 40, and for BRCA2 carriers between 40 and 45, typically after completion of childbearing. This procedure has been shown to substantially reduce the risk of ovarian cancer as well as fallopian tube malignancies, significantly improving long-term outcomes for BRCA-Positive women.

Risk-Reducing Mastectomy (RRM)

Risk-reducing mastectomy should also be considered, with a thorough discussion of its benefits and limitations. While RRM effectively lowers the risk of breast cancer in BRCA-Positive individuals, it is important to address the psychological and social implications of such a major surgical intervention. Comprehensive counselling and support are essential to help patients make informed, personalised decisions.

Hormone Replacement Therapy Post-Surgery

For premenopausal BRCA-Positive women who have undergone risk-reducing salpingo-oophorectomy, HRT may be considered to manage menopausal symptoms while balancing cancer risk. Careful selection and multidisciplinary oversight are essential.

Hover over each box for more detailed information!

Indications for HRT

Considered for symptom management in premenopausal women.

HRT may be offered to BRCA-Positive women post-surgery, especially those without a personal history of breast cancer, to alleviate menopausal symptoms and maintain quality of life.

Type of HRT

Oestrogen-only HRT preferred after hysterectomy.

When the uterus has been removed, oestrogen-only HRT is generally recommended, as combined HRT may increase breast cancer risk. Choice of therapy should be personalised based on risk profile.

Multidisciplinary Decision Making

Collaborative care ensures personalised risk management.

Decisions about HRT should involve a team of gynaecologists, oncologists, and endocrinologists to balance cancer risk, symptom relief, and quality-of-life considerations for each BRCA-Positive patient.

Tailored post-surgical care. Individualised HRT planning with multidisciplinary input ensures BRCA-Positive women receive optimal management for menopausal symptoms while minimising cancer risk.

Multidisciplinary and Patient-Centred Care

Effective management of women who are BRCA-Positive requires a truly multidisciplinary approach. Collaboration between genetics specialists, gynaecologists, oncologists, and psychologists is essential to address the complex medical and emotional needs of these patients.

By integrating expertise from multiple disciplines, clinicians can provide comprehensive care that not only focuses on cancer prevention and surveillance but also considers the psychological impact and quality of life of BRCA-Positive individuals. Personalised, patient-centred strategies ensure that decisions regarding surveillance, surgery, and hormone therapy are made collaboratively, respecting the patient’s preferences and overall wellbeing.

Cascade Testing and Family Communication

Cascade genetic testing is a crucial strategy for identifying relatives who may be at risk of being BRCA-Positive. By systematically offering genetic testing to family members of affected individuals, clinicians can detect high-risk carriers early, enabling timely interventions and preventative measures.

This approach not only reduces the overall incidence of hereditary breast and ovarian cancer but is also cost-effective, minimising unnecessary medical expenses. Open and sensitive communication with families ensures that relatives understand their potential risks and the importance of genetic assessment, thereby promoting proactive health management across generations.

Quality of Life and Long-Term Health

For women who are BRCA-Positive and have undergone risk-reducing interventions, ongoing attention to long-term health is essential. This includes monitoring bone density, cardiovascular health, sexual function, and psychological wellbeing.

Hormone replacement therapy (HRT) can mitigate some of the adverse effects associated with premature menopause following risk-reducing salpingo-oophorectomy. However, long-term safety data remain limited, emphasising the need for continued research and careful patient follow-up.

By adopting a holistic approach that addresses both medical and quality-of-life outcomes, clinicians can ensure that BRCA-Positive women receive comprehensive, patient-centred care that extends beyond cancer prevention.

Conclusion: Holistic Management for BRCA-Positive Women

Early identification and comprehensive management of BRCA-Positive women are essential for optimising outcomes and reducing the risk of breast and ovarian cancers.

Practical recommendations include timely genetic testing, individualised surveillance, consideration of risk-reducing surgery, appropriate hormone replacement therapy, and multidisciplinary care. Equally important is addressing psychological wellbeing and quality-of-life concerns, ensuring care extends beyond purely medical interventions.

By integrating these strategies, clinicians can provide BRCA-Positive women with a holistic, patient-centred approach that addresses both cancer risk and long-term health, empowering them to make informed decisions about their care.

Take action today – consult with genetic and oncology specialists to explore personalised strategies for surveillance, risk reduction, and proactive management of hereditary cancer risk.

Book a Consultation

References

National Comprehensive Cancer Network (NCCN). Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate. Version 2025.07.10.
Nelson HD, Pappas M, Cantor A, Haney E, Holmes R. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2019;322(7):666–685. doi:10.1001/jama.2019.8430
Chen LM, Modesitt SC. Hereditary Cancer Syndromes and Risk Assessment. American College of Obstetricians and Gynecologists (ACOG), Practice Guideline. 2019.
Caruso G, Weroha SJ, Cliby W. Ovarian Cancer. JAMA. 2025; doi:10.1001/jama.2025.9495
Hassan H, Allen I, Rahman T, et al. Long-Term Health Outcomes of Bilateral Salpingo-Oophorectomy in BRCA1 and BRCA2 Pathogenic Variant Carriers With Personal History of Breast Cancer: A Retrospective Cohort Study Using Linked Electronic Health Records. Lancet Oncol. 2025;26(6):771–780. doi:10.1016/S1470-2045(25)00156-1
National Comprehensive Cancer Network (NCCN). Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer. Version 2025.07.16.
Chen LM, Blank SV, Burton E, et al. Reproductive and Hormonal Considerations in Women at Increased Risk for Hereditary Gynecologic Cancers. Fertil Steril. 2019;112(6):1034–1042. doi:10.1016/j.fertnstert.2019.07.1349
Petrucelli N, Daly MB, Pal T. BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer. GeneReviews® [Internet]. Updated 2025 Mar 20.
AlHilli MM, Batur P, Hurley K, et al. Comprehensive Care of Women With Genetic Predisposition to Breast and Ovarian Cancer. Mayo Clin Proc. 2023;98(4):597–609. doi:10.1016/j.mayocp.2023.01.001
Walker A, Marmelstein B, Fillman C, et al. Genetic Counseling and Subsequent Cascade Genetic Testing for Women With a Family History of Pathogenic BRCA1 Mutation: A Cost-Effectiveness Model. J Clin Oncol. 2024;42(Suppl 16):10621. doi:10.1200/JCO.2024.42.16_suppl.10621

Dr Ehsan Karimiani

Dr Ehsan Karimiani (MD, MRes, PhD) is a distinguished London-based Clinical Geneticist and a leading figure in the field of rare inherited conditions. With over a hundred scientific publications to his name, he masterfully bridges advanced clinical expertise with internationally recognised genomic research. Dr. Karimiani specialises in risk assessment, cancer genetics, and delivering clear, tailored guidance to families navigating complex hereditary information. A true global advocate, he is committed to raising the profile of medical genomics and promoting the vital role of genetic counselling across diverse international communities.